Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Other Non Operating Income (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Other Non Operating Income for 15 consecutive years, with $1.9 million as the latest value for Q1 2026.

  • Quarterly Other Non Operating Income fell 57.75% to $1.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $12.3 million through Jan 2026, up 57.6% year-over-year, with the annual reading at $10.4 million for FY2025, 212.47% up from the prior year.
  • Other Non Operating Income for Q1 2026 was $1.9 million at PharmaCyte Biotech, up from -$95.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $10.4 million in Q2 2025, with the low at -$1.5 million in Q3 2023.
  • Average Other Non Operating Income over 5 years is $1.4 million, with a median of -$155.5 recorded in 2024.
  • The sharpest move saw Other Non Operating Income plummeted 37073.58% in 2023, then surged 1773617.79% in 2025.
  • Over 5 years, Other Non Operating Income stood at -$3906.0 in 2022, then surged by 104426.68% to $4.1 million in 2023, then crashed by 100.03% to -$1062.0 in 2024, then skyrocketed by 91.05% to -$95.0 in 2025, then skyrocketed by 1995747.37% to $1.9 million in 2026.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at $1.9 million, -$95.0, and -$121.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.